Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.
- Author:
Sang Yong SHIN
1
;
Seung Tae LEE
;
Hyun Young KIM
;
Chang Hun PARK
;
Hee Jin KIM
;
Jong Won KIM
;
Seok Jin KIM
;
Won Seog KIM
;
Sun Hee KIM
Author Information
- Publication Type:Original Article
- Keywords: Lymphoplasmacytic lymphoma; MYD88 L265P; Aspirate; MEMO-PCR
- MeSH: B-Lymphocytes*; Bone Marrow; Humans; Lymphoma; Lymphoma, Non-Hodgkin*; Methods; Prevalence; Waldenstrom Macroglobulinemia*
- From:Blood Research 2016;51(3):181-186
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Recent studies have identified a high prevalence of the MYD88 L265P mutation in lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM) cases, whereas low frequencies have been observed in other B cell non-Hodgkin lymphomas (NHLs). METHODS: We evaluated the sensitivity of the mutant enrichment 3'-modified oligonucleotide (MEMO)-PCR technique, a new detection method. We examined the MYD88 L265P mutation in a series of Korean patients with LPL/WM and other B cell NHLs in bone marrow aspirates, using the MEMO-PCR technique. RESULTS: The sensitivity of MEMO-PCR was estimated to be approximately 10-16.7%. MYD88 L265P was detected in 21 of 28 LPL cases (75%) and only three of 69 B cell NHL cases (4.3%). CONCLUSION: Although MEMO-PCR had relatively low sensitivity, we confirmed the high prevalence of the MYD88 L265P mutation in Korean LPL patients. Our study suggests the diagnostic value of MYD88 L265P for differentiating B-cell NHLs.
